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Although targeting of the death receptors (DRs) DR4 and DR5 still appears a suitable antitumoral strategy, the limited clinical
responses to recombinant soluble TNF-related apoptosis inducing ligand (TRAIL) necessitate novel reagents with improved
apoptotic activity/tumor selectivity. Apoptosis induction by a single-chain TRAIL (scTRAIL) molecule could be enhanced
410-fold by generation of epidermal growth factor receptor (EGFR)-speciﬁc scFv-scTRAIL fusion proteins. By forcing
dimerization of scFv-scTRAIL based on scFv linker modiﬁcation, we obtained a targeted scTRAIL composed predominantly of
dimers (Db-scTRAIL), exceeding the activity of nontargeted scTRAIL B100-fold on Huh-7 hepatocellular and Colo205 colon
carcinomacells.IncreasedactivityofDb-scTRAILwasalsodemonstratedontarget-negativecells,suggestingthat,inadditionto
targeting, oligomerization equivalent to an at least dimeric assembly of standard TRAIL per se enhances apoptosis signaling.
In the presence of apoptosis sensitizers, such as the proteasomal inhibitor bortezomib, Db-scTRAIL was effective at picomolar
concentrations in vitro (EC50 B2 10
 12 M). Importantly, in vivo, Db-scTRAIL was well tolerated and displayed superior
antitumoral activity in mouse xenograft (Colo205) tumor models. Our results show that both targeting and controlled
dimerization of scTRAIL fusion proteins provides a strategy to enforce apoptosis induction, together with retained tumor
selectivity and good in vivo tolerance.
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The TNF-related apoptosis-inducing ligand (TRAIL; Apo2L/
Dulanermin) as well as TRAIL-agonistic antibodies are able to
kill a broad range of tumor cell lines in vitro, are well tolerated
in vivo and thus applicable for therapy of cancer.
1,2 None-
theless, clinical trials revealed that the use of soluble,
recombinant TRAIL, given alone or in combination with other
drugs, may be often insufﬁcient to gain signiﬁcant therapeutic
effects. For example, in a phase II trial focusing on treatment
of patients with relapsed follicular non-Hodgkin’s lymphoma
(NHL), the response rate of the anti-CD20 antibody rituximab
was not improved when TRAIL was given in combination.
3
Accordingly, the improvement of TRAIL-based therapies
should address the apparent shortcomings of present TRAIL
reagents, namely short in vivo half-life and low speciﬁc
bioactivity. In addition, sensitization of tumor cells toward the
apoptosis-inducing activity of TRAIL appears particularly
relevant.
Resistance to TRAIL-induced apoptosis can be caused by
the expression levels and composition of proapoptotic and
decoy TRAIL receptors as well as by intracellular mechan-
isms. The cell surface expression of death receptor (DR)4 or
DR5 is a prerequisite for TRAIL-mediated apoptosis, but is
insufﬁcientincaseofblockedintracellularpathways.Levelsof
inhibitor of apoptosis proteins, such as X-linked inhibitor of
apoptosis protein (XIAP), have been shown to be critical
determinants of TRAIL sensitivity in melanoma.
4 In hepato-
cellular carcinoma (HCC), several factors including the
decreased expression of CD95 (Apo1/Fas),
5 activation of
transcription factor nuclear factor-kB (NF-kB)
6 or overexpres-
sion of pro-inﬂammatory cytokines and their receptors
7
accompany such dysregulation of apoptotic signaling. How-
ever,TRAILhasbeenshowntoinducecelldeathselectivelyin
HCC when tumor cells are sensitized by chemotherapeutics
like the multi-kinase inhibitor sorafenib
8 and the proteasome
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9,10 The clinical relevance of TRAIL
receptor (TRAILR)-directed therapy of HCC is emphasized
by current studies
11 (see also http://clinicaltrials.gov/ct2/
show/study/NCT01258608).
Different approaches have been taken to enhance speciﬁc
apoptotic activity and maintain high tumor selectivity of
recombinant TRAIL molecules. Thus, TRAIL mutants, acting
predominantly on either DR4 or DR5, facilitate cell death
induction, for example on DR5-positive tumor cells, without
the need for membrane immobilization or crosslinking of
soluble TRAIL.
12,13 Alternatively, TRAIL can be fused to
antibodies directed against tumor markers. It has been shown
for CD33-directed scFv-TRAIL that such fusion proteins are
superior over antibody-targeted chemotherapeutics because
of stronger cytotoxic activity and the minimization of side
effects on normal nontransformed cells.
14 Correct trimeriza-
tion and zinc coordination of recombinant TRAIL therapeutics
seem to be crucial for biological activity and for nonreactivity
toward nontransformed cells, in particular hepatocytes.
15 Our
previous results showed that three extracellular domains of
human TRAIL can be fused by peptide linkers to yield highly
active single-chain TRAIL (scTRAIL) that can be further
endowed with target-dependent activity by fusion to an
antibody derivative.
16 Such antigen-binding scFv-scTRAIL
molecules functionally mimic the natural membrane-
expressed TRAIL and are more effective therapeutics than
scTRAIL alone.
16 We here sought to develop a concept for
controlled oligomerization of scFv-scTRAIL fusion proteins
leading to improved expression and stability as well
as increased functional activity under retention of tumor
selectivity.
Results
Construction and preparation of scTRAIL fusion
proteins. For generation of functionally improved scFv-
scTRAIL fusion proteins, scTRAIL was ﬁrst genetically
optimized for mammalian expression. Additionally, the
linker motifs in the molecule were reduced from (GGGS)4
to (GGGS)2, potentially making the protein more rigid and
less prone to aggregation without affecting apoptosis
induction (data not shown).
In this study, we used epidermal growth factor receptor
(EGFR), an established tumor marker overexpressed in
several carcinomas, including colon, lung and liver cancer,
17
as a model for targeting. The chimeric monoclonal antibody
cetuximab (C225) is directed against the extracellular domain
of EGFR and blocks receptor activation by interfering with
ligand binding.
18 This antibody was approved for treatment of
advanced metastatic colorectal cancer, squamous cell carci-
noma of the head and neck, and is evaluated in non-small
cell lung cancer (NSCLC).
19,20 A humanized single-chain Fv
fragment (scFv) ‘huC225’ (RE Kontermann, unpublished data)
derived from cetuximab was fused to the N-terminus of scTRAIL,
yielding scFvaEGFR-scTRAIL (Figure 1a). The aim of this
work was the improvement of the proapoptotic activity of
scFvaEGFR-scTRAIL fusion proteins under retention of tumor
selectivity, that is, nonreactivity toward normal, nonmalignant
tissue. TRAIL bioactivity depends on the oligomerization
state,inparticularrelevantforTRAILR2(DR5),whichispoorly
activated by soluble, trimeric forms of TRAIL.
21,22 As DR5
appears to be the major mediator of apoptosis signaling in the
vast majority of carcinoma cells, we reasoned that a dimeric
variant of scFvaEGFR-scTRAIL should combine tumor target-
ing with an even more enhanced DR5 activation. Dimerization
was accomplished by reducing the linker between VH
(variable domain of immunoglobulin heavy chain) and VL
(variable domain of immunoglobulin light chain) from
(GGGGS)3 to GGGGS as described for the so-called
diabodies,
23 yielding DbaEGFR-scTRAIL.
scFvaEGFR-scTRAIL and DbaEGFR-scTRAIL were produced
and puriﬁed with yields of 43mg highly pure protein per liter
cell culture supernatant. SDS-PAGE and immunoblotting
revealed single bands with molecular masses of B70kDa
for scTRAIL and B100kDa for scFvaEGFR-scTRAIL and
DbaEGFR-scTRAIL, matching the calculated values of 68
and 94kDa (93kDa for DbaEGFR-scTRAIL), respectively
(Figure 1b). The size exclusion chromatography of scTRAIL
and scFvaEGFR-scTRAIL (Figure 1c) indicated a monomeric
composition for the majority of the protein (494%). Interest-
ingly, DbaEGFR-scTRAIL was present in a heterogeneous
state with a major peak corresponding to the expected dimer
and a minor peak representing putative trimers or tetramers.
Upon separation of both isoforms, equal amounts of the
higher-orderisoformsandthedimerdisplayedinvitroidentical
bioactivity (data not shown) indicating that higher than dimeric
forms of scTRAIL oligomers apparently do not further
enhance apoptosis signaling.
EGFR-speciﬁc binding of scTRAIL fusion proteins. The
speciﬁc binding of scTRAIL fusion proteins to EGF receptors
was analyzed by ﬂow cytometry of Huh-7 cells, displaying
moderate EGFR expression compared with HepG2 cells
with barely detectable EGFR (Supplementary Figure S1).
ScFvaEGFR-scTRAIL and DbaEGFR-scTRAIL binding was
detectable on Huh-7 and HepG2 cells, but competition
of fusion protein binding by preincubation of cells with the
anti-EGFR scFv huC225 (2mM) was only possible on Huh-7
cells (Figure 2a). Moreover, Huh-7 cell binding of Alexa 488
(Life Technologies, Darmstadt, Germany) labeled EGFR-
speciﬁc cetuximab was blocked by preincubation with 0.5mM
DbaEGFR-scTRAIL (Figure 2b). The intermediate ﬂuorescence
signal observed upon competition of fusion protein binding on
Huh-7 cells likely reﬂects the binding of the scTRAIL moiety to
TRAIL receptors and is consistent with the low but speciﬁc
signal obtained from scFvaEGFR-scTRAIL and DbaEGFR-scTRAIL
binding to TRAILR
þ EGFR
  HepG2 cells. Binding compe-
tition of both fusion proteins with EGFR-speciﬁc antibody/
scFv on EGFR
þ cells is evidence for the structural integrity
and functionality of the scFv and diabody targeting modules
of the fusion proteins.
Quantitative binding studies of scTRAIL fusion proteins to
EGFR
þ, DR4
þDR5
þ NCI-H460 cells revealed signiﬁ-
cantly different (P¼0.003) EC50 values for scFvaEGFR-
scTRAIL (3.6±0.3 10
 10M) and DbaEGFR-scTRAIL
(1.6±0.3 10
 10M), implicating an avidity effect of the
speciﬁc molecular composition of the divalent DbaEGFR-
scTRAIL and therefore potentially superior targeting compared
with scFvaEGFR-scTRAIL (Figure 2c). To investigate whether
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Cell Death and Diseaseor not the cetuximab-derived, humanized scFv has retained in
itsdivalentdiabodyformatthe functionalactivityofcetuximab,
we checked for blocking of EGF-induced EGFR autopho-
sphorylation by DbaEGFR-scTRAIL, whereby cetuximab
served as a positive control. Functional blocking of EGF-
stimulated receptor activation by the divalent DbaEGFR-
scTRAIL could be demonstrated for both Colo205
(Figure 2d, left panel) and Huh-7 (Figure 2d, right panel) cells.
Target-independent induction of cell death by scTRAIL
fusion proteins. To investigate the basic bioactivity of
scTRAIL fusion proteins without the inﬂuence of targeting
domains, we analyzed cell death induction on the target-
negative cell lines HepG2 (hepatoma) and Jurkat (T-cell
leukemia) and compared it with scTRAIL devoid of a
targeting domain (Table 1 and Figure 3a). On HepG2 cells,
DbaEGFR-scTRAIL exerted an B10-fold increased bioactivity
compared with scFvaEGFR-scTRAIL and a commercially
available, highly active ‘KillerTRAIL’ (Figure 3a, left panel).
Because of the EGFR deﬁciency of HepG2 cells, the
proapoptotic activities of DbaEGFR-scTRAIL and scFvaEGFR-
scTRAIL were not inﬂuenced by the presence of an at least
sevenfold excess (70nM) of the EGFR-blocking cetuximab
(not shown). Accordingly, the bioactivity of scFvaEGFR-
scTRAIL did not differ from that one of scTRAIL. On
EGFR
 , DR4
 DR5
weak Jurkat cells, which are known to be
sensitive for apoptosis induced by TRAIL oligomers, again
we found a higher proapoptotic activity of DbaEGFR-scTRAIL
compared with KillerTRAIL and, as expected, no reactivity
toward non-oligomerized scFvaEGFR-scTRAIL or scTRAIL
(Figure 3a, right panel), underlining the target-independent
higher apoptotic activity of the dimeric scTRAIL fusion
protein.
EGFR-directed enhancement of cell death by scTRAIL
fusion proteins. The EGFR
þ human colon carcinoma
Colo205 and liver carcinoma Huh-7 were chosen to
demonstrate the enhancement in bioactivity achievable by
the receptor targeting capacity of scFvaEGFR-scTRAIL and
DbaEGFR-scTRAIL. Both cell lines require sensitization by
either cycloheximide (CHX) or bortezomib to reveal efﬁcient
TRAIL-mediated apoptosis induction in vitro (Figure 3b).
Compared with scTRAIL, the enhancement in bioactivity of
the monovalent scFvaEGFR-scTRAIL was B16-fold on Huh-7
cells and B6-fold on Colo205 cells, whereby Colo205
expressed less EGFR compared with Huh-7 (Figure 3b and
Supplementary Figure S1). Interference with EGFR binding
by co-incubation with an excess of cetuximab (70nM)
revealed a right shift of the dose-response curve of
scFvaEGFR-scTRAIL toward the EC50 of nontargeted
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Figure 1 Biochemical analysisof scTRAILandscTRAILfusion proteins. (a) Design of novel scTRAILfusionproteins. Three humanTRAIL domains(aa residues95–281)
were fused with (GGGS)2 peptide linkers yielding single-chain TRAIL. EGFR-speciﬁc scFv antibody fragments comprising VH and VL were fused N-terminally to scTRAIL.
(GGGGS)3 or GGGGS peptide linkers between VH and VL were chosen to obtain a scFv or a diabody conﬁguration, respectively. L, VH leader; F, FLAG tag. (b) Puriﬁed
scTRAIL(1),scFvaEGFR-scTRAIL(2)andDbaEGFR-scTRAIL(3)wereanalyzedbyreducingSDS-PAGEandsilverstaining(upper,1mgprotein/lane)orimmunoblotting(lower,
250ng protein/lane) againstTRAIL or FLAG.(c)scTRAILand derived fusionproteins were separatedby size exclusion chromatography. Thyroglobulin(669kDa), b-amylase
(200kDa), bovine serum albumin (67kDa) and carbonic anhydrase (29kDa) were used as standard proteins
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Cell Death and DiseasescTRAIL (Table 1), pointing to an improvement of scTRAIL
bioactivity by EGFR targeting. DbaEGFR-scTRAIL, repre-
senting a dimeric assembly of scFv-scTRAIL, showed an
B10-fold enhanced bioactivity compared with monovalent
scFvaEGFR-scTRAIL and an B100-fold enhancement com-
pared with nontargeted scTRAIL. To further assess
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Figure 2 Receptor interaction of EGFR-speciﬁc scTRAIL fusion proteins. (a) Binding of DbaEGFR-scTRAIL and scFvaEGFR-scTRAIL to target-negative HepG2 and target-
positiveHuh-7cells(thin-linedhistograms).Furthermore,cellswerepreincubated withan excessofanti-EGFRscFvbeforeaddingscTRAILfusionproteins(boldhistograms).
Filled histograms, controls without scTRAIL fusion proteins. (b) Blocking of the binding of Alexa Fluor 488-labeled cetuximab to HepG2 and Huh-7 by an excess of DbaEGFR-
scTRAIL (bold histograms). Thin-lined histograms, cetuximab alone; ﬁlled histograms, isotype controls. (c) Dose-response relationship of scTRAIL fusion protein binding to
EGFR
þ NCI-H460 cells by indirect immunoﬂuorescence ﬂow cytometry to reveal concentration of half-maximum binding (EC50) (mean±S.E.M., n¼4). (d) Colo205 and
Huh-7 cells were serum-starved overnight and then incubated with 2nM of DbaEGFR-scTRAIL, cetuximab and PBS for control, respectively. After 10min, 50ng/ml EGF was
addedandcellswereincubatedforadditional20minfollowedbycelllysis.EGFreceptorswereimmunoprecipitatedusingaspeciﬁcmousemonoclonalantibodyandsubjected
to SDS-PAGE followed by immunoblotting with phosphotyrosine antibody (top). Total amounts of EGFR were determined by reprobing the membrane with EGFR-speciﬁc
rabbit polyclonal antibody (bottom)
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Cell Death and DiseaseTable 1 EC50 values (mean±S.E.M.) of various TRAIL constructs on tumor cells in the presence of bortezomib/cycloheximide
HepG2 Colo205 Huh-7
DbaEGFR-scTRAIL 5.4±3.1 10
 11M 2.1±0.3 10
 12M 2.7±0.5 10
 12M
DbaEGFR-scTRAIL+Cetuximab 4.3±0.4 10
 12M 1.6±0.5 10
 11M
scFvaEGFR-scTRAIL 5.8±2.7 10
 10M 2.8±0.3 10
 11M 4.3±1.2 10
 11M
scFvaEGFR-scTRAIL+Cetuximab 1.9±0.4 10
 10M 5.0±2.3 10
 10M
scTRAIL 5.3±2.3 10
 10M 1.8±0.5 10
 10M 7.0±2.3 10
 10M
KillerTRAIL 2.4±0.5 10
 10M
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Figure 3 Target-independentandEGFR-targetedinductionofcelldeathbyscTRAILfusions.(a)HepG2cells(left)weresensitizedwith 350ng/mlbortezomibandtreated
with serial dilutions of DbaEGFR-scTRAIL (squares), KillerTRAIL (ﬁlled triangles), scFvaEGFR-scTRAIL (circles) or scTRAIL (open triangles). After 16h, number of viable cells
was determined using crystal violet staining (mean±S.E.M., n¼4). Nonsensitized Jurkat cells (right) were assayed analogously, followed by determination of cell viability
using the MTT method (mean±S.E.M., n¼3). (b) Colo205 colon carcinoma (left and middle, mean±S.E.M., n¼3) or Huh-7 hepatocarcinoma cells (right, mean±S.E.M.,
n¼4) were sensitized with bortezomib (left, 400ng/ml; right, 250ng/ml) or CHX (middle, 2.5mg/ml) and treated with 0.63nM (left) or serial dilutions of DbaEGFR-scTRAIL
(open squares), scFvaEGFR-scTRAIL (open circles) or scTRAIL (triangles). After 16h, cell viability was determined using crystal violet staining (Huh-7) or the MTT method
(Colo205). For quantiﬁcation of the targeting effect, cells were preincubated with an excess of cetuximab (70nM) before adding DbaEGFR-scTRAIL (ﬁlled squares) and
scFvaEGFR-scTRAIL (ﬁlled circles). (c) Huh-7 cells were assayed essentially as in (b), but preincubated with constant concentrations of DbaEGFR-scTRAIL (squares),
scFvaEGFR-scTRAIL (circles) or scTRAIL (triangles), followed by addition of serial dilutions of bortezomib (mean±S.E.M., n¼3). Control (asterisk), bortezomib alone
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Cell Death and Diseaseapoptosis sensitization by bortezomib, Huh-7 cells were
pretreated with a ﬁxed dose of the scTRAIL fusion proteins
followed by titration of bortezomib (Figure 3c). At a protein
concentration of X1nM, the tested reagents DbaEGFR-
scTRAIL, scFvaEGFR-scTRAIL and scTRAIL did not differ in
their ability to induce apoptosis in the presence of
bortezomib. In contrast, at protein concentrations of
p0.1nM, the superior activity of targeted scTRAIL fusion
proteins became visible, with DbaEGFR-scTRAIL as the most
potent apoptosis inducer.
A nearly complete block of cell death by either pan-caspase
(z-Val-Ala-Asp-ﬂuoromethylketone (zVADfmk)) or caspase-3
selective(z-Asp-Glu-Val-Asp-ﬂuoromethylketone(zDEVDfmk))
inhibitors (Figure 4a) and failure of necrostatin-1 to prevent
or reduce cell death (data not shown) indicated that Huh-7
and Colo205 undergo predominantly apoptotic cell death
upon treatment with scTRAIL fusion proteins. Cetuximab
blocked EGF-induced autophosphorylation of EGF receptors
(Figure 2d). It is well known that cetuximab only blocks ligand-
dependent but not ligand-independent receptor tyrosine
kinase (RTK) activity as a complete, divalent antibody but
not as a monovalent antigen-binding fragment (Fab).
24
Moreover, on appropriate target cells, cetuximab can exert
growth-inhibitory and/or apoptosis-inducing activity,
19
suggesting a possible contribution of the divalent EGFR
targeting domain of DbaEGFR-scTRAIL to the enhanced
apoptosis induction. However, for the tumor cells studied
here, we obtained no evidence for a TRAIL-independent cell
death-inducing function of the targeting domain of DbaEGFR-
scTRAIL. First, as for the monovalent targeted scFvaEGFR-
scTRAIL, in vitro cotreatment of DbaEGFR-scTRAIL with 70nM
cetuximab resulted in a decrease in bioactivity to the level of
nontargeted scTRAIL rather an increase in apoptosis
(Figure 3b).Furthermore, cetuximab by itself, though blocking
EGF-inducedautophosphorylationofEGFRinColo205andin
Huh-7 cells (Figure 2d), did not substantially affect growth of
these two cancer cell lines in a 4-day culture (Figures 4b
and c). Similarly, when DbaEGFR-scTRAIL-induced apoptosis
was prevented, either by the presence of neutralizing anti-
TRAIL antibodies in DbaEGFR-scTRAIL-treated Colo205 cell
cultures(Figure4b)orbytreatingHuh-7cellcultureswithpan-
caspase inhibitors (Figure 4c), only a marginal growth
inhibition was noted during the 4-day observation period.
Together, for the cells and the in vitro conditions studied here,
thedataindicatethat(1)DbaEGFR-scTRAIL-inducedcelldeath
requires TRAIL signaling and (2) blocking EGFR function by
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Figure 4 Caspase dependence of cell death and impact of the anti-EGFR diabody moiety of DbaEGFR-scTRAIL. (a) Colo205 cells (left) and Huh-7 cells (right) were
sensitizedwith25 and250ng/mlbortezomib,respectively,andtreatedwithdifferentconcentrationsofDbaEGFR-scTRAILwithorwithoutthepresenceofpan-caspaseinhibitor
zVADfmkor caspase-3inhibitor zDEVDfmk (both inhibitors20mM for Colo205and 10mM for Huh-7). After 16h, cellviability was determined using MTTstaining (Colo205)or
crystal violet staining (Huh-7) and data were normalized using bortezomib-treated cells as control (mean±S.E.M., n¼3). (b)1 10
4 Colo205 cells per well were grown in
96-well plates using medium with 0.1% FCS. Upon stimulation with 50ng/ml EGF and sensitization with 10ng/ml bortezomib, cells were incubated with equimolar
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(open squares), DbaEGFR-scTRAILþzVADfmk (ﬁlled squares), cetuximab (open circles) or cetuximabþzVADfmk (ﬁlled circles) for 3 days and cell viability was assayed by
the MTT method using bortezomib-treated cells and bortezomib/zVADfmk-treated cells, respectively, as control for normalization (mean±S.E.M., n¼3)
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Cell Death and Diseasethe diabody module does not contribute to rapid apoptosis
induction.
In vivo tolerance of DbaEGFR-scTRAIL. In order to
investigate the in vivo properties of the novel fusion protein,
we ﬁrst checked for potential hepatotoxic effects of DbaEGFR-
scTRAIL and monovalent scFvaEGFR-scTRAIL in comparison
with aggregated Fas ligand used as a positive control.
To this, serum alanine aminotransaminase (serum ALT) and
liver caspase-3 activities were assayed in mice after application
of a high dose of the protein (1nmol). Both assays consistently
revealed that a DbaEGFR-scTRAIL dose inducing maximum
apoptosis in vitro did not cause acute liver toxicity in vivo
(Figure 5). Thus, mean serum ALT activities at 4h after
application of DbaEGFR-scTRAIL (61U/l) or scFvaEGFR-scTRAIL
(50U/l) were only slightly and transiently raised to values
considered as upper normal level (50U/l) in humans and
declined to baseline after 24h (Figure 5a). Analyses of
caspase-3 activities from mouse liver tissue 24h (5h for
positive control) after in vivo fusion protein application
(Figure 5b) and histological analyses of liver tissue sections
(Supplementary Figure S2) revealed no evidence for acute
tissue toxicity of the applied reagents. Furthermore, a
comparison of Huh-7 hepatoma cells and primary human
hepatocytes (PHHs) for caspase-3 activation by DbaEGFR-
scTRAIL in the presence of bortezomib showed a strong,
bortezomib-dependent caspase-3 activation in the tumor cells,
whereas normal liver cells were neither affected by the scTRAIL
fusion protein alone nor in combination with bortezomib
(Figure 5c). These results were conﬁrmed by immunoblot
analysis of cleaved caspase-3 in Huh-7 and PHHs, with no
detectable caspase activation in combination-treated PHHs,
whereas robust caspase processing was detectable in sensitive
Huh-7 carcinoma cells (Figure 5d).
Antitumoral activity of DbaEGFR-scTRAIL in a xenograft
tumor model. We investigated the in vivo antitumoral
activity of DbaEGFR-scTRAIL in nude mice carrying Colo205
carcinomas (Figure 6). Given the in vitro data, showing
superior bioactivity of DbaEGFR-scTRAIL compared with
scFvaEGFR-scTRAIL or scTRAIL in particular at low protein
concentrations, eight doses of 0.45nmol protein were
injected intraperitoneally (i.p.) in a daily regimen in
combination with bortezomib cotreatment every second
day. The systemic treatment started after establishment of
solid, vascularized tumors, and tumor growth was monitored
for 22 days. Bortezomib treatment by itself did not interfere
with progressive tumor growth, whereas scTRAIL and
scFvaEGFR-scTRAIL both delayed tumor growth but, at the
low dosage applied, did not induce regression of tumors. In
contrast, upon DbaEGFR-scTRAIL treatment, a strong
reduction of tumor size and prolonged survival in all
animals, with macroscopically undetectable tumors in 11/12
(þbortezomib) and 9/12 (w/o bortezomib) cases, was
recorded (Figure 6). Interestingly, under the treatment
conditions applied, there was only a slight, but statistically
not signiﬁcant, beneﬁt of cotreatment with bortezomib,
although at termination of treatment the combination group
presented with slower regrowth of tumors (Figure 6a).
Discussion
In this study we present a new format of TRAIL fusion
proteins based on directed dimerization with strongly
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Cell Death and Diseaseincreased tumor-targeted bioactivity and devoid of systemic
toxicity of these TRAIL fusion proteins. We and others
previously showed that proapoptotic ligands of the TNF family
can be engineered to exert stronger antitumor activity by
creation of single-chain molecules
25 and by targeting death
ligands to cell surface-expressed tumor antigens by fusion
to a tumor-speciﬁc scFv.
16,26 Tumor-targeted scFv-TRAIL
fusionproteinscanmimicthenaturallymembrane-boundform
of the ligand enabling DR4- and particularly DR5-mediated
apoptosis induction, which is poorly exerted by soluble forms
of TRAIL.
21,27,28 In support of this, we have recently shown
that a fusion protein comprising scFv and single-chain TRAIL
is a preferred format compared with nontargeted TRAIL in
terms of bioactivity in vitro and in vivo.
16
Aside from targeting through scFv, bioactivity of death
ligands can be considerably increased through oligomeriza-
tion.
29 However, this may lead to generalized systemic
toxicity, particularly evident for acute liver toxicity induced
by Fas-speciﬁc reagents.
30 Similarly, for TRAIL, off-target
toxicity of uncontrolled oligomeric forms of TRAIL has been
reported.
31 We reasoned that a combination of antigen
targeting and controlled TRAIL oligomerization should, on
respective target cells, result in an effective activation of
TRAIL DRs, and in particular DR5, which is the major
proapoptotic TRAILR in carcinoma cells.
32 With the forced
dimerization of scFvaEGFR-scTRAIL fusion proteins by short-
ening the linkers between VH and VL to ﬁve amino-acid
residues, we generated a DbaEGFR-scTRAIL fusion protein
exhibiting bivalent antigen binding and dimeric scTRAIL
conﬁguration, which meets the above criteria. In addition to
the dimers, a minor species of higher molecular mass, likely
trimeric or tetrameric fusion proteins, was detected by gel
ﬁltration of afﬁnity-puriﬁed DbaEGFR-scTRAIL. We assume
thatthe scTRAILmoiety ofthefusionproteinhasanadditional
inﬂuenceonoligomerization,becausehigher-orderoligomeric
species were not found when the aEGFR diabody was
expressed as a single protein (data not shown). However,
we propose that such oligomeric assemblies do not provide
a further advantage with regard to bioactivity, compared
with the dimeric DbaEGFR-scTRAIL form. First, cell death
assays using the separated species gave no hint for
a different bioactivity of both isoforms. Second, an engi-
neered protein format with an at least trimeric assembly
of scFvaEGFR-scTRAIL showed again no better activity
in vitro as compared with DbaEGFR-scTRAIL (A Benk and
M Siegemund, unpublished data).
We found that DbaEGFR-scTRAIL has a higher afﬁnity to
target-positive tumor cells than scFvaEGFR-scTRAIL, evident
from an approximately twofold lower EC50 at 41C. Both the
diabodyconﬁgurationandthedimericstatusofscTRAILcould
contribute to this apparent afﬁnity increase. However, we
attribute this largely to a better avidity of the bivalent diabody
targeting module, as dynamic clustering of TRAILRs and
therefore stable receptor ligand interactions are prevented
under the applied assay conditions. Independent evidence for
increased avidity of DbaEGFR-scTRAIL is obtained from the
reduced efﬁcacy of cetuximab in competing the binding
of DbaEGFR-scTRAIL to EGFR
þ cells as compared with
scFvaEGFR-scTRAIL. Accordingly, we postulate that a more
stable receptor interaction of DbaEGFR-scTRAIL supports
clustering and subsequent DISC formation of death receptors
in speciﬁc membrane compartments, for example lipid rafts,
which have been proposed to play an important role in DR4
and DR5 signal transduction.
33,34 Our data support this
reasoning by showing enhanced bioactivity of the DbaEGFR-
scTRAIL molecules, to which both targeting and the dimeric/
oligomeric assembly of the TRAIL molecule itself contribute,
resultinginanoverallgreater100-foldincreasedbioactivityon
target-positive tumor cells. In contrast, on target-negative
tumor cell lines like HepG2 or Jurkat, the dimeric scTRAIL
conﬁguration exclusively seems to contribute to an activity
increase compared with scTRAIL.
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Cell Death and DiseaseThe DbaEGFR-scTRAIL comprises two scFvs derived from
the mAb cetuximab, an EGF-blocking, antagonistic antibody
reported to be capable of growth inhibition and/or apoptosis
induction in some tumor cells.
19,20 Although we conﬁrmed
blocking of EGF-induced EGFR autophosphorylation in the
tumor cells studied here, it was interesting to note that this
RTK inhibition did not apparently contribute to the enhance-
ment of TRAIL-induced apoptosis, at least as detectable
withinshort-terminvitroassays.Lackofanactivecontribution
of EGFR blocking to apoptosis sensitivity was particularly
evidentfromarightshiftinthedose-responsecurvestoalevel
of nontargeted TRAIL molecules when cetuximab was added
to DbaEGFR-scTRAIL-treated cells. Moreover, the block of
DbaEGFR-scTRAIL-mediated cell death by TRAIL-neutralizing
antibodies conﬁrms that the apoptotic signal emanated from
TRAILRs. Accordingly, the strongly enhanced apoptotic
activity of DbaEGFR-scTRAIL is an intrinsic molecular feature
of this bifunctional protein, in which EGFR targeting and
presentation of TRAIL to its cognate DRs cannot be mimicked
by cooperative action of two independent molecules, one
interfering with EGFR activity and one inducing apoptosis via
TRAIL DRs. However, these in vitro studies do not rule out a
contribution of EGFR inhibition by the scFv module in the
observed in vivo antitumoral activity of DbaEGFR-scTRAIL,
where several additional parameters aside from basal
apoptosis sensitivity affect tumor outgrowth and responsive-
ness to drug treatment.
Strongly enhanced bioactivity and improved pharmacoki-
netics of targeted scTRAIL fusion proteins (see Schneider
et al.
16 and this study) appear mandatory to reach signiﬁcant
clinical responses under TRAIL therapy. However, consider-
ingpreviousreportsonthepotentiallossoftumorselectivityof
aggregated or artiﬁcially crosslinked TRAIL forms,
15,35,36 the
oligomeric nature of DbaEGFR-scTRAIL demands a thorough
analysis of potential off-target action and systemic toxicity.
Toward this end, we obtained evidence that DbaEGFR-
scTRAIL was surprisingly well tolerated in mice at doses up
to 3mg/kg with no evidence for acute hepatotoxicity, judged
from ALT levels and histopathological analyses. In vitro
DbaEGFR-scTRAIL treatment of primary human hepatocytes
with or without apoptosis sensitizer bortezomib did not induce
caspase activation, thus fully conﬁrming the mouse in vivo
data. Additionally, healthy human liver tissue from in vitro
cultures proved to be resistant toward DbaEGFR-scTRAIL in
the presence of the apoptosis sensitizer bortezomib also
(H Bantel et al., unpublished data).
On top of a good in vivo tolerance, a superior in vivo
antitumoral activity of DbaEGFR-scTRAIL against xenotrans-
planted Colo205 cells was found. Interestingly, in this in vivo
tumor model, DbaEGFR-scTRAIL was very effective even in
the absence of the apoptosis sensitizer bortezomib, although
after termination of short-term therapy, tumor regrowth was
detectable earlier in this group as compared with the
combination therapy group. A potentially greater beneﬁt of
combination therapy might become evident under a different
therapeutic regimen and/or only in long-term studies. In
contrast, in preliminary in vivo studies with the hepatocellular
carcinoma cells Huh-7, the antitumoral activity of different
scTRAIL derivatives, including DbaEGFR-scTRAIL, was only
revealed in the presence of bortezomib (A Vogel, unpublished
data), which corresponded to the strict dependence of in vitro
TRAIL sensitivity on bortezomib ofthis particular cell line. This
is in accordance with published data of bortezomib as an
effective sensitizer of apoptosis.
9,37
In conclusion, we have shown that by genetic engineering,
controlled dimerization and tumor targeting can be combined
to create bifunctional fusion proteins with enforced apoptosis
induction under maintenance of systemic tolerance, which
exceeds the functional activities of conventional and other
antigen-targeted TRAIL molecules. Speciﬁcally, combining
targeting domains with intrinsic antagonistic activity toward a
targeted growth factor receptor with death ligands engineered
for improved apoptotic activity could potentially synergize to
further enhance the antitumor activity. Although for the tumor
model studied here, this bifunctionality of DbaEGFR-scTRAIL
appeared dispensable for in vitro apoptosis induction, it might
beofparticularrelevanceinvivofortumorsthatarestillgrowth
factor dependent. Becauseof themodular nature ofthe fusion
protein, the concept shown here for EGFR targeting can be
exploited for a broad range of tumors for which selective cell
surface markers are known.
Materials and Methods
Plasmids and cell lines. The pIRESpuro-scTRAIL expression construct for
human scTRAIL was obtained by EcoRI/NotI cloning of a synthesized sequence
encoding three TRAIL modules (aa residues 95–281) connected by (GGGS)2
linkers into a construct described previously.
16
For generation of the EGFR-speciﬁc pCR3-scFv-scTRAIL expression construct,
a synthesized coding sequence of a humanized scFv ‘huC225’ (RE Kontermann,
unpublished data) was ampliﬁed using the oligonucleotides 50-CGAGGTGCAGCT
GGTCGAG-30 and 50-TGCGGCCGCTCTCTTGATTTC-30. Next, this template was
annealed with the oligonucleotide 50-ATATATCTCGAGGCCAGCGACTACAAAG
ACGATGACGATAAAGGAGCCGAGGTGCAGCTGGTCGAG-30 to insert an XhoI
site and a FLAG tag coding sequence. After strand elongation, the oligonucleotides
50-ATATATCTCGAGGCCAGCGAC-30 and 50-ATATGAATTCTGCGGCCGCTCTC
TTGATTTC-30 were used for PCR. The product was cloned via XhoI/EcoRI
into pCR3 (Invitrogen, Karlsruhe, Germany), carrying a VH leader and a dummy
scFv-scTRAIL sequence. The scTRAIL coding sequence of this construct
16
was then substituted with scTRAIL ((GGGS)2 linkers) via EcoRI/XbaI.
The EGFR-speciﬁc pCR3-Db-scTRAIL expression construct was derived from
pCR3-scFvaEGFR-scTRAIL by shortening the scFv linker from (GGGGS)3 to
GGGGS. Therefore, two PCR products were generated using the oligonucleotides
(1) 50-CCCACAGCCTCGAGGCCAG-30 and (2) 50-GAGCCGCCACCGCCACT
AG-30 as well as (3) 50-CTAGTGGCGGTGGCGGCTCTGATATTCAGCTGACC
CAGTCC-30 and (4) 50-TGAATTCTGCGGCCGCTCTC-30. After annealing of the
products at the underlined regions and strand elongation, the whole sequence was
ampliﬁed by the oligonucleotides (1) and (4) followed by XhoI/NotI cloning into
pCR3-scFvaEGFR-scTRAIL.
HEK293, HepG2, NCI-H460, Colo205 and Jurkat cells were obtained from the
ATCC (Manassas, VA, USA). Huh-7 cells were obtained from the JCRB (Osaka,
Japan). Cells were cultured in RPMI-1640 medium (Invitrogen) supplemented with
5% fetal calf serum (FCS; HyClone, South Logan, UT, USA), excepting HepG2,
Colo205 and Huh-7, where 10% FCS was added to the medium. PHHs were
isolated according to a well-deﬁned standard procedure.
38
Production and puriﬁcation of recombinant proteins. TRAIL fusion
proteins were produced in HEK293 cells as published,
16 and puriﬁed from
supernatants ﬁrst by immobilized metal afﬁnity chromatography (IMAC) based on
afﬁnity of TRAIL to Ni-NTA-Agarose (Qiagen, Hilden, Germany). After elution with
100mM imidazol in IMAC buffer (50mM NaH2PO4, pH 8.0, 300mM NaCl) and
dialysis against PBS, the proteins were further puriﬁed by afﬁnity chromatography
using anti-FLAG mAb M2 agarose (Sigma-Aldrich, Steinheim, Germany) according
to the manufacturer’s protocol. ScTRAIL was puriﬁed by M2 agarose only. After
elution of bound proteins with 100mg/ml FLAG peptide (Peptides & elephants,
Potsdam, Germany) and dialysis against PBS, proteins were concentrated with
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Cell Death and DiseaseVivaspin devices (PES membrane with 50 or 10kDa molecular weight cutoff;
Sartorius Stedim, Aubagne, France). The protein concentration was measured with
aspectrophotometer(NanoDropProducts,Wilmington,DE,USA)andaliquotswere
stored at  801C.
Immunoprecipitation and protein analysis. For immunoprecipitations,
cells were lysed on ice in RIPA buffer (50mM Tris, pH 7.5, 150mM NaCl, 10mM
sodiumﬂuoride,20mMb-glycerophosphate,1mMEDTA,1%NP-40,1mMsodium
orthovanadate, 0.5mM phenylmethylsulfonyl ﬂuoride, 0.1% SDS, 0.25% sodium
deoxycholate) with Complete protease inhibitor (Roche Diagnostics, Mannheim,
Germany) and lysates were clariﬁed by centrifugation (16000 g, 10min, 41C).
Then, 1.5mg lysate protein was incubated with 1.5mg mouse anti-EGFR Ab-13
mAb (Neomarkers, Fremont, CA, USA) under gentle shaking at 41C overnight.
Immune complexes were captured with protein G sepharose (KPL, Gaithersburg,
MD, USA) and washed three times with RIPA buffer. Proteins were analyzed by
SDS-PAGEandwesternblottingusingmouseanti-phosphotyrosineP-Tyr-100mAb
(Cell Signaling Technology, Danvers, MA, USA) and rabbit anti-EGFR 1005
antibody(SantaCruzBiotechnology,SantaCruz,CA,USA)followedbyhorseradish
peroxidase (HRP)-conjugated secondary antibodies. Enhanced chemolumine-
scence (ECL; Pierce Biotechnology, Rockford, IL, USA) was used for visualization.
Caspases were detected by immunoblotting using a rabbit polyclonal anti-
body against cleaved caspase-3 (Cell Signaling Technology). Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) as internal control was detected with a
rabbit polyclonal antibody (Cell Signaling Technology). HRP-conjugated secondary
antibodies (Zymed Laboratories, San Francisco, CA, USA) and ECL were used for
visualization.
Afﬁnity-puriﬁed scTRAIL fusion proteins were analyzed by SDS-PAGE and
silver staining (Sigma-Aldrich). For western blotting, anti-TRAIL MAB687
(R&D Systems, Wiesbaden, Germany) and anti-FLAG M2 mAbs (Sigma-Aldrich)
were used, followed by anti-mouse alkaline phosphatase-coupled secondary
antibody(Sigma-Aldrich) for detection. For size exclusionchromatography, proteins
were applied to a BioSuite250 HR SEC 300 7.8 HPLC column (Waters, Milford,
MA, USA) equilibrated in PBS and eluted at a ﬂow rate of 0.5ml/min.
Flow cytometry. 5 10
5 cells were suspended in PBA buffer (PBS, 0.025%
BSA, 0.02% NaN3) and incubated for 1h at 41C with the scTRAIL fusion proteins
(2mg/ml). After washing the cells three times with PBA buffer, bound proteins were
detected by anti-human TRAIL mAb MAB687 (2.5mg/ml) and ﬂuorescein
isothiocyanate (FITC)-labeled rabbit anti-mouse IgG Ab (1:200, Sigma-Aldrich),
followed by three washing steps with PBA each. For blocking of scTRAIL fusion
protein binding to EGFRs, a divalent variant of scFv huC225 (scFv huC225Cys,
50mg/ml, kindly provided by Celonic GmbH, Ju ¨lich, Germany) was added 30min
before incubation with scFvaEGFR-scTRAIL or DbaEGFR-scTRAIL, respectively.
TRAIL receptors were detected by anti-TRAIL R1 mAb MAB347 and anti-TRAIL R2
mAb MAB6311 (4mg/ml each, R&D Systems) in conjunction with anti-mouse IgG-
FITC. EGF receptors were detected by a phycoerythrin-labeled anti-human EGFR
mAb sc-101 (4mg/ml, Santa Cruz Biotechnology). For binding competition, puriﬁed
DbaEGFR-scTRAIL (50mg/ml) was added 30min before incubation with Alexa Fluor
488-coupled (Life Technologies) mAb cetuximab (1mg/ml).
Binding of scTRAIL fusion proteins to EGFR-expressing NCI-H460 cells was
analyzedbyﬂowcytometryat41Casdescribed.
39,40Cellswereincubatedwithanti-
TRAIL mAb MAB687 (2.5mg/ml) and FITC-labeled rabbit anti-mouse IgG Ab
(1:200) in the presence of cell-bound protein or without (background control). Data
were ﬁtted with Prism (GraphPad Software, La Jolla, CA, USA) from four
independent binding curves, and mean EC50 values±S.E.M. were calculated. For
statistical analysis, Student’s t-test was applied.
Cell death assays. Huh-7 (2.5 10
4 per well), HepG2 (3 10
4 per well),
Colo205 (5 10
4 per well) or Jurkat cells (1 10
5 per well) were grown in 100ml
culture medium in 96-well plates for 24h, followed by treatment with serial dilutions
of scTRAIL fusion proteins or ‘KillerTRAIL’ (Enzo Life Sciences, Lo ¨rrach, Germany)
in triplicates. For positive control, cells were killed with 0.25% Triton X-100. Cell
death assays were performed in the absence or presence of bortezomib
(20–250ng/ml for Huh-7, 350ng/ml for HepG2, 10–400ng/ml for Colo205;
Selleck Chemicals, Houston, TX, USA) or CHX (2.5mg/ml for Colo205; Sigma-
Aldrich). Bortezomib/CHX was added 30min before incubation with the
proapoptotic ligands to sensitize carcinoma cells for cell death induction.
Appropriate concentrations of caspase inhibitors zVADfmk and zDEVDfmk
(10mM stock solutions in DMSO; Enzo Life Sciences) were added to the
bortezomib solution. Where applicable, the EGFR signaling pathway was induced
by 50ng/ml EGF (Sigma-Aldrich). Alternatively, cells were preincubated for 30min
with the proapoptotic ligands followed by addition of serial dilutions of bortezomib.
After 16h of incubation, cell viability was determined either by crystal violet staining
(Huh-7, HepG2) or the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT)method(Jurkat,Colo205).
41FortheMTTassay,cellswerelysedinDMF/H2O
(1:1),15%SDS,pH4.5.Todemonstratetargetantigen-dependentinductionofcell
death,cellswerepreincubatedfor30minwithcompetingcetuximabmAb(10mg/ml,
Merck KGaA, Darmstadt, Germany) or alternatively scFv huC225Cys (10mg/ml).
For inhibition of TRAIL bioactivity, neutralizing anti-TRAIL antibody 2E5 (1mg/ml,
Enzo Life Sciences) was used.
ALT and caspase activities. Groups of three CD1 mice (Janvier, Le
Genest-St-Isle, France) were treated i.p. with 1nmol DbaEGFR-scTRAIL and
scFvaEGFR-scTRAIL, 0.1nmol FasL fusion protein (positive control) and PBS
(negative control). Blood samples were taken from the tail after 4 and 24h and
incubated on ice. Clotted blood was centrifuged (10000 g, 10min, 41C) and
serum samples were stored at  801C. Activity of ALT was determined by an
enzymatic assay (BIOO Scientiﬁc, Austin, TX, USA). To determine caspase-3
activity in the liver tissue, mice were killed after 24h (positive control after 5h) and
liver biopsies were taken. Homogenates were prepared in lysis buffer (200mM
NaCl, 20mM Tris, 1% NP-40, pH 7.4). Then, 10mg of protein was analyzed by
conversion of the ﬂuorogenic substrate Ac-Asp-Met-Gln-Asp-7-Amino-4-
methylcoumarin (Ac-DMQD-AMC; Enzo Life Sciences). Caspase activity in PHH
and Huh-7 cells was determined as published.
42
Xenograft mouse tumor model. Female NMRI nu/nu mice (Janvier), 8
weeks old, were injected subcutaneously (s.c.) with 3 10
6 Colo205 cells in 100ml
PBS at left and right dorsal sides. Treatment started 6 days after tumor cell
inoculationwhentumorsreachedB100mm
3.Micereceived8dailyi.p.injectionsof
0.45nmol of the afﬁnity-puriﬁed TRAIL fusion proteins. On days 1, 3, 5 and 7 of
treatment, mice received additionally 5mg bortezomib in 100ml PBS i.p. 3h before
protein injection. The control groups received 100ml PBS or 5mg bortezomib at the
same time intervals. Tumor growth was monitored as described.
16,43 Tukey’s test
was applied for statistics.
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